Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

BACKGROUND: The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational monoclonal antibody with high affinity and bind...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Desai, Jayesh, Deva, Sanjeev, Lee, Jong Seok, Lin, Chia-Chi, Yen, Chia-Jui, Chao, Yee, Keam, Bhumsuk, Jameson, Michael, Hou, Ming-Mo, Kang, Yoon-Koo, Markman, Ben, Lu, Chang-Hsien, Rau, Kun-Ming, Lee, Kyung-Hun, Horvath, Lisa, Friedlander, Michael, Hill, Andrew, Sandhu, Shahneen, Barlow, Paula, Wu, Chi-Yuan, Zhang, Yun, Liang, Liang, Wu, John, Paton, Virginia, Millward, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Clinical/Translational Cancer Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7295442/
https://ncbi.nlm.nih.gov/pubmed/32540858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000453
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia